

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

Provisional stakeholder list of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • Merck Sharp & Dohme (pembrolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Breast Cancer Care and Breast Cancer Now • Breast Cancer UK • Cancer Black Care • Cancer Equality • Haven • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Wellbeing of Women • Women's Health Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Institute of Radiology • British Psychosocial Oncology Society • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists | <p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (docetaxel, doxorubicin, epirubicin, paclitaxel) • Celgene (nab-paclitaxel, paclitaxel) • Hospira UK (docetaxel, paclitaxel) • Janssen-Cilag (doxorubicin) • Medac (doxorubicin, epirubicin, paclitaxel) • Mylan (epirubicin) • Pfizer (doxorubicin, epirubicin) • Seacross Pharmaceuticals (docetaxel, doxorubicin, paclitaxel) • Teva (doxorubicin) |

Provisional stakeholder list for the technology appraisal of pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

Issue date: July 2019

© National Institute for Health and Care Excellence 2019. All rights reserved.

Page 1 of 3

| Consultees | Commentators (no right to submit or appeal) |
|--|---|
| <ul style="list-style-type: none"> • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Breast Cancer Group • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS North Somerset CCG • NHS Vale of York CCG • Welsh Government | <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Against Breast Cancer • Breast Cancer Hope • Breast Cancer Research Trust • Cochrane Breast Cancer Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Pro-Cancer Research Fund <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.